News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
575,533 Results
Type
Article (46261)
Company Profile (186)
Press Release (529086)
Section
Business (163838)
Career Advice (2554)
Deals (29768)
Drug Delivery (90)
Drug Development (75527)
Employer Resources (153)
FDA (13806)
Job Trends (13154)
News (288551)
Policy (28045)
Tag
Academia (2589)
Alliances (41884)
Alzheimer's disease (1255)
Approvals (13718)
Artificial intelligence (117)
Bankruptcy (314)
Best Places to Work (10302)
Biotechnology (150)
Breast cancer (103)
Cancer (889)
Cardiovascular disease (81)
Career advice (2136)
Cell therapy (198)
Clinical research (59592)
Collaboration (304)
Compensation (96)
COVID-19 (2486)
C-suite (76)
Data (819)
Diabetes (125)
Diagnostics (5611)
Drug pricing (74)
Earnings (56293)
Employer resources (139)
Events (82913)
Executive appointments (240)
FDA (14209)
Funding (279)
Gene therapy (152)
GLP-1 (568)
Government (4106)
Healthcare (16333)
Infectious disease (2562)
Inflammatory bowel disease (102)
Interviews (525)
IPO (13273)
Job creations (3131)
Job search strategy (1775)
Layoffs (399)
Legal (6050)
Lung cancer (163)
Manufacturing (143)
Medical device (10551)
Medtech (10555)
Mergers & acquisitions (16503)
Metabolic disorders (353)
Neuroscience (1508)
NextGen Class of 2024 (5797)
Non-profit (4045)
Northern California (1066)
Obesity (204)
Opinion (217)
Patents (95)
People (52879)
Phase I (18488)
Phase II (26263)
Phase III (19832)
Pipeline (198)
Postmarket research (2347)
Preclinical (7652)
Radiopharmaceuticals (222)
Rare diseases (181)
Real estate (4983)
Regulatory (19037)
Research institute (2217)
Resumes & cover letters (382)
Southern California (992)
Startups (3250)
United States (10107)
Vaccines (530)
Weight loss (165)
Date
Last 7 days (725)
Last 30 days (2428)
Last 365 days (32845)
2024 (27807)
2023 (36251)
2022 (46925)
2021 (50436)
2020 (48456)
2019 (41463)
2018 (31529)
2017 (29014)
2016 (27716)
2015 (32200)
2014 (26133)
2013 (22320)
2012 (21469)
2011 (22435)
2010 (20016)
Location
Africa (804)
Arizona (113)
Asia (35948)
Australia (7255)
California (2407)
Canada (1066)
China (199)
Colorado (94)
Connecticut (103)
Europe (80420)
Florida (349)
Georgia (79)
Illinois (284)
Indiana (164)
Kansas (85)
Maryland (463)
Massachusetts (1848)
Michigan (130)
Minnesota (212)
New Jersey (724)
New York (747)
North Carolina (605)
Northern California (1066)
Ohio (107)
Pennsylvania (613)
South America (1100)
Southern California (992)
Texas (335)
Washington State (300)
575,533 Results for "pharmacyte biotech formerly known as nuvilex".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
PharmaCyte Biotech, Inc. today announced a $7 million investment in MyMD Pharmaceuticals, Inc.
May 21, 2024
·
4 min read
Business
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide.
November 15, 2023
·
4 min read
Business
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
Femasys Inc. today announced a strategic upfront investment of $6.85 million by public biotech company, PharmaCyte Biotech, Inc. (Nasdaq: PMCB) and other healthcare investors.
November 15, 2023
·
6 min read
BioMidwest
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech, Inc. provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration for guidance on further development of the technology.
October 31, 2023
·
4 min read
Deals
5 Radiopharma Biotechs to Watch for Potential Buyouts
Big Pharma can’t seem to get enough radiopharmaceutical biotechs. With Lilly, Sanofi and BMS chasing Novartis into the complex space, all eyes are on these specialty biotechs.
October 9, 2024
·
5 min read
·
Annalee Armstrong
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock.
February 2, 2023
·
4 min read
Career Advice
Breaking Into Biotech: What You Must Know to Enter Industry
Candidates looking to enter biotech should focus on cultivating key skills, thoughtfully crafting their resumes and putting their best, most authentic foot forward in interviews. An internship, co-op or fellowship won’t hurt, either.
October 31, 2024
·
6 min read
·
Angela Gabriel
Deals
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest.
May 11, 2023
·
7 min read
BioMidwest
PharmaCyte Biotech Announces Final Results of Tender Offer
PharmaCyte Biotech, Inc. announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest.
June 15, 2023
·
4 min read
Obesity
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs
Eli Lilly CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as biotechs press on with compelling data.
October 9, 2024
·
3 min read
·
Annalee Armstrong
1 of 57,554
Next